iepo | Inhaled epoprostenol for acute respiratory distress syndrome ..

Keyword	CPC	PCC	Volume	Score	Length of keyword
iepo	1.13	0.8	6178	60	4

Keyword	CPC	PCC	Volume	Score
ieponline	1.09	0.3	8799	91
ieponline k12 wa	1.45	0.2	1399	87
iepol	1.98	0.2	1164	34
ieport	1.54	0.5	3906	93
iepoch	0.69	0.8	131	67
iepox	1.61	0.2	6738	67
iepose	1.94	0.4	6407	95
ie power	1.41	0.2	7780	76
ipod	1.7	0.4	5133	2
iepoch panasonic tw	1.71	0.9	1903	38
iepomasqui	1.7	0.2	3497	16
ieponline medical lake school district	0.04	0.2	2531	52
ieponline xep wa	0.5	0.9	4161	42
ieponline.aast.edu	1.96	0.7	4905	68
ieponline washing	1.19	0.9	5452	95
ieponline and edmonds	1.33	0.4	5631	67
iefponline cursos	1.17	0.8	9751	27

Search Results related to iepo on Search Engine

Inhaled epoprostenol for acute respiratory distress syndrome ... - LWW
lww.com

https://journals.lww.com/nursingcriticalcare/Fulltext/2018/07000/Inhaled_epoprostenol_for_acute_respiratory.2.aspx

WEBJul 13, 2018 · Acute respiratory distress syndrome (ARDS) is associated with high rates of mortality. Inhaled nitric oxide and inhaled epoprostenol (iEPO) are inhaled pulmonary vasodilators used for adjunctive management in patients with severe ARDS. This article describes the safe and effective use of iEPO in patients with refractory hypoxemia.

DA: 26 PA: 54 MOZ Rank: 24

The Use of Inhaled Epoprostenol for Acute Respiratory Distress …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852286/

WEBNov 17, 2021 · Inhaled epoprostenol (iEpo) is a pulmonary vasodilator used to treat refractory respiratory failure, including that caused by Coronavirus 2019 (COVID-19) pneumonia. Aim of Study. To describe the experience at three teaching hospitals using iEpo for severe respiratory failure due to COVID-19 and evaluate its efficacy in …

DA: 49 PA: 22 MOZ Rank: 91

INHALED PULMONARY VASODILATOR TREATMENT FOR COVID …
chestnet.org

https://journal.chestnet.org/article/S0012-3692(21)01990-5/fulltext

WEBInhaled pulmonary vasodilators, epoprostenol (iEPO) and nitric oxide (iNO), are used as adjunctive therapies for the treatment of refractory hypoxemia in patients with acute respiratory distress syndrome (ARDS). Hypoxemia in COVID-19 patients is mainly caused by ventilation-perfusion mismatch, which might be improved by inhaled pulmonary ...

DA: 10 PA: 87 MOZ Rank: 26

Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581066/

WEBOct 19, 2020 · Inhaled pulmonary vasodilators, such as inhaled epoprostenol (iEPO) and inhaled nitric oxide (iNO), have been shown to improve hypoxemia by increasing blood flow to well-ventilated portions of the lung, leading to improvements in ventilation and perfusion matching (8–10).

DA: 52 PA: 61 MOZ Rank: 63

Unexpected Interruptions in the Inhaled Epoprostenol Delivery …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522871/

WEBOct 14, 2021 · Inhaled epoprostenol (iEpo) is a synthetic prostacyclin analog that is used off-label as a selective pulmonary vasodilator (SPV) in critically ill patients with refractory hypoxemia, right ventricular failure, and postcardiac …

DA: 81 PA: 44 MOZ Rank: 34

Inhaled Epoprostenol Compared With Nitric Oxide for Right …
ahajournals.org

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062464

WEBJul 4, 2023 · Inhaled pulmonary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essential therapeutics for the prevention and medical management of postoperative RVF. However, there is limited evidence from clinical trials to guide agent selection despite the significant cost considerations of iNO therapy.

DA: 3 PA: 74 MOZ Rank: 54

The Use of Inhaled Epoprostenol for Acute Respiratory Distress …
nih.gov

https://pubmed.ncbi.nlm.nih.gov/35274053/

WEBNov 17, 2021 · Abstract. Introduction: Inhaled epoprostenol (iEpo) is a pulmonary vasodilator used to treat refractory respiratory failure, including that caused by Coronavirus 2019 (COVID-19) pneumonia. Aim of study: To describe the experience at three teaching hospitals using iEpo for severe respiratory failure due to COVID-19 and evaluate its …

DA: 80 PA: 42 MOZ Rank: 71

Acute Respiratory Distress Syndrome: Diagnosis and …
aafp.org

https://www.aafp.org/pubs/afp/issues/2020/0615/p730.html

WEBJun 15, 2020 · AARON SAGUIL, MD, MPH, AND MATTHEW V. FARGO, MD, MPH. Am Fam Physician. 2020;101 (12):730-738. Author disclosure: No relevant financial affiliations. Acute respiratory distress syndrome (ARDS) is ...

DA: 26 PA: 69 MOZ Rank: 46

Inhaled Epoprostenol Pharmacology Therapy in Pulmonary …
springer.com

https://link.springer.com/chapter/10.1007/978-3-031-44626-9_14

WEBFeb 3, 2024 · Inhaled epoprostenol (iEPO) is an effective pulmonary vasodilator that can improve right ventricular performance. iEPO dilates the pulmonary blood vessels and decreases the RV afterload. iEPO can produce selective vasodilatory effect without inducing systemic side effects. iEPO can be administered to patients receiving high-flow nasal …

DA: 25 PA: 9 MOZ Rank: 65

In-vitro and in-vivo comparisons of high versus low …
biomedcentral.com

https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01827-4

WEBAug 21, 2021 · Inhaled epoprostenol (iEPO), a naturally occurring prostaglandin that acts as vascular smooth muscle relaxant, has been utilized clinically for over two decades and has been shown to reduce pulmonary artery pressure [ 1, 2, 3, 4, 5] and improve oxygenation [ 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ].

DA: 94 PA: 13 MOZ Rank: 39